Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma(ABC-102) | withdrawn | Phase 1 / Phase 2 | 0 | RedHill Biopharma LimitedINDUSTRY | 1 | Dec 7, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 |
| Dec 2, 2017 |
| clinicaltrials |
| NCT00428194 | Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer | withdrawn | Phase 1 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00944580 | A Vaccine Study for High Risk Cancers | withdrawn | Phase 1 | 0 | Penn State UniversityOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT02719015 | Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT00562185 | Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Julie E. Bauman, MD, MPHOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02106871 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC) | withdrawn | Phase 1 | 0 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02630420 | Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer | withdrawn | Phase 1 | 0 | Yale UniversityOTHER | 0 | Oct 26, 2017 | clinicaltrials |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Oct 6, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT03283046 | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 20, 2017 | clinicaltrials |
| NCT00124956 | Doxorubicin Pharmacokinetic (PK) Study | withdrawn | Phase 1 / Phase 2 | 0 | Boston Children's HospitalOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | withdrawn | Phase 1 | 0 | Robert FerrisOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02745756 | A Combined Cell Therapy Approach to the Treatment of Neuroblastoma | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Aug 30, 2017 | clinicaltrials |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Aug 28, 2017 | clinicaltrials |
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma(MUKfourteen) | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02674555 | A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jul 28, 2017 | clinicaltrials |
| NCT02489266 | In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 27, 2017 | clinicaltrials |
| NCT02210104 | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 21, 2017 | clinicaltrials |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT01130623 | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01182883 | A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01236586 | RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01386502 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | withdrawn | Phase 1 / Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT02915172 | Lenvatinib and Capecitabine in Patients With Advanced Malignancies | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 26, 2017 | clinicaltrials |
| NCT02439788 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA(GINAKIT) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00637117 | Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma. | withdrawn | Phase 1 / Phase 2 | 0 | Baylor Research InstituteOTHER | 0 | Jun 12, 2017 | clinicaltrials |
| NCT02194374 | Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 12, 2017 | clinicaltrials |
| NCT02483871 | Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT02570958 | ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors(ENB-RIGGS) | withdrawn | Phase 1 | 0 | St. Joseph's Healthcare HamiltonOTHER | 0 | Jun 5, 2017 | clinicaltrials |
| NCT02647190 | Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 2, 2017 | clinicaltrials |
| NCT02829840 | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 2, 2017 | clinicaltrials |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01843738 | Radiation Use During Vemurafenib Treatment | withdrawn | Phase 1 | 0 | University of UtahOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT02595242 | Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma | withdrawn | Phase 1 | 0 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT01361945 | AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Texas Tech University Health Sciences Center, El PasoOTHER | 0 | May 9, 2017 | clinicaltrials |
| NCT01483274 | Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation(AML) | withdrawn | Phase 1 | 0 | University of LouisvilleOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01969942 | A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma(ASCT) | withdrawn | Phase 1 | 0 | University of LouisvilleOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT02564536 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT02791919 | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | May 3, 2017 | clinicaltrials |
| NCT00603460 | DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of PennsylvaniaOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02251639 | Diagnostic Aids for Detection and Diagnosis of Oral Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 27, 2017 | clinicaltrials |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Apr 25, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 7, 2017source: clinicaltrials